Novo Nordisk Expands Wegovy Distribution to Strengthen Market Position

Novo Nordisk is reinforcing its position in the obesity treatment market with Wegovy, a key competitor to Eli Lilly’s Mounjaro, by expanding its distribution network and improving operational efficiency.

According to industry sources, the company will add Chong Kun Dang as an additional wholesale distributor for Wegovy starting March 25, alongside its existing partner Zuellig Pharma. Given the product’s temperature sensitivity, distribution will involve multiple pharmaceutical wholesalers equipped with cold-chain capabilities to supply hospitals, clinics, and pharmacies.

Until now, Zuellig Pharma has exclusively handled distribution of Wegovy, as well as other Novo Nordisk products such as Ozempic and insulin. The new arrangement introduces Chong Kun Dang—already a co-promotion and marketing partner since late last year—into the wholesale supply chain, further strengthening collaboration between the two companies.

Novo Nordisk’s distribution agreement with Zuellig Pharma remains in place through December 2028, with Chong Kun Dang newly added rather than replacing the existing partner.

Market attention has also focused on adjustments to distribution margins. While some industry participants noted changes in disclosed margins, Novo Nordisk has clarified that these adjustments do not constitute a reduction in the actual supply price.

Previously, margin structures varied depending on negotiations between Zuellig Pharma and individual distributors, creating challenges in oversight and inconsistencies across the supply chain. The addition of Chong Kun Dang is expected to help improve alignment in pricing and margin structures, enhancing transparency and predictability for both the company and its partners.

Wegovy remains competitively priced across dosage levels, and the updated distribution strategy is expected to support broader market access. Given that treatment typically extends from several months to over a year in clinical practice, the changes are seen as a move to strengthen long-term market competitiveness without altering base pricing.